UK Stocks-Factors to watch on March 5
- ByReuters-
March 5 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening open 58 points lower at 6,593 on Friday, according tofinancial bookmakers.* EMISSIONS: Britain still has not set...
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
March 5 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening open 58 points lower at 6,593 on Friday, according tofinancial bookmakers.* EMISSIONS: Britain still has not set...
(Adds futures, news items)March 4 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening 80 points lower at 6,595 on Thursday, according tofinancial bookmakers, with futures...
March 4 (Reuters) - Britain's FTSE 100 .FTSE index is seenopening 80 points lower at 6,595 on Thursday, according tofinancial bookmakers.* CAR SALES: British new car registrations...
Saying that Moderna (NASDAQ:MRNA) was the best performing COVID-19 vaccine stock in the past year would be a laughable understatement. Shares of AstraZeneca (NASDAQ:AZN) gained...
This article was written exclusively for Investing.comCrude oil returns to $40 per barrel pivot point; XLE makes a comebackNatural gas tumbles going into peak demand seasonRunoff...
The stock market generally moves up or down based on investor expectations about the future. October's market performance, during which the major indices endured their worst weekly...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Strong Sell | Neutral |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 162.00 | 162.00 | 162.00 | -8.00 | -4.71% | 599.05K | Lagos | |||
| 7.05 | 7.10 | 6.75 | -0.05 | -0.70% | 31.25M | Lagos | |||
| 31.50 | 31.80 | 31.05 | -0.20 | -0.63% | 15.50M | Lagos | |||
| 25.30 | 25.65 | 25.30 | -0.25 | -0.98% | 38.65M | Lagos | |||
| 7.95 | 8.15 | 7.75 | -0.30 | -3.64% | 26.78M | Lagos | |||
| 1.73 | 1.72 | 1.72 | -0.190 | -9.95% | 471.84K | Lagos | |||
| 0.60 | 0.00 | 0.00 | -0.04 | -6.15% | 1.63M | Lagos | |||
| 14.65 | 14.65 | 14.65 | -1.60 | -9.85% | 1.07M | Lagos | |||
| 1,350.00 | 1,350.00 | 1,350.00 | 0.00 | 0.00% | 71.83K | Lagos | |||
| 5.00 | 5.00 | 5.00 | -0.20 | -3.85% | 2.15M | Lagos | |||
| 5.05 | 5.10 | 5.05 | -0.05 | -0.98% | 1.82M | Lagos | |||
| 0.76 | 0.00 | 0.00 | -0.08 | -9.52% | 2.61M | Lagos | |||
| 2.89 | 2.90 | 2.90 | -0.10 | -3.33% | 1.24M | Lagos | |||
| 0.83 | 0.00 | 0.00 | 0.000 | 0.00% | 16.61M | Lagos | |||
| 0.40 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00K | Lagos |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.